Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs

Bibliography

• Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351(18):1860-73
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111(6):2962-72
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111(5):2516-20
   PubMed Web of Science ®Google Scholar
• Ocio EM, Mateos MV, Maiso P, New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008;9(12):1157-65
   PubMed Web of Science ®Google Scholar
• Anderson KC. New insights into therapeutic targets in myeloma. Hematol Am Soc Hematol Educ Program 2011;2011:184-90
   PubMed Web of Science ®Google Scholar
• Arrigo AP, Tanaka K, Goldberg AL, Welch WJ. Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature 1988;331(6152):192-4
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59(11):2615-22
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61(7):3071-6
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Catley LP, Hideshima T, Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62(17):4996-5000
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348(26):2609-17
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352(24):2487-98
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110(10):3557-60
   PubMed Web of Science ®Google Scholar
• Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801-47
   PubMed Web of Science ®Google Scholar
• Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999;68:1015-68
   PubMed Web of Science ®Google Scholar
• Lowe J, Stock D, Jap B, Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995;268(5210):533-9
   PubMed Web of Science ®Google Scholar
• Unno M, Mizushima T, Morimoto Y, The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure 2002;10(5):609-18
   PubMed Web of Science ®Google Scholar
• Ciechanover A, Schwartz AL. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 1998;95(6):2727-30
   PubMed Web of Science ®Google Scholar
• Rivett AJ, Hearn AR. Proteasome function in antigen presentation: immunoproteasome complexes, Peptide production, and interactions with viral proteins. Curr Protein Pept Sci 2004;5(3):153-61
   PubMed Web of Science ®Google Scholar
• Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004;16(1):76-81
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002;99(22):14374-9
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Akiyama M, Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101(4):1530-4
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson PG, Anderson KC. Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol 2003;7(2):191-204
   PubMedGoogle Scholar
• Carvalho P, Goder V, Rapoport TA. Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER proteins. Cell 2006;126(2):361-73
   PubMed Web of Science ®Google Scholar
• Raasi S, Wolf DH. Ubiquitin receptors and ERAD: a network of pathways to the proteasome. Semin Cell Dev Biol 2007;18(6):780-981
   PubMed Web of Science ®Google Scholar
• Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 1999;18(49):6867-74
   PubMed Web of Science ®Google Scholar
• Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002;7(1):9-16
   PubMed Web of Science ®Google Scholar
• Altun M, Galardy PJ, Shringarpure R, Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 2005;65(17):7896-901
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12(5):431-40
   PubMed Web of Science ®Google Scholar
• Demo SD, Kirk CJ, Aujay MA, Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67(13):6383-91
   PubMed Web of Science ®Google Scholar
• Parlati F, Lee SJ, Aujay M, Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009;114(16):3439-47
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110(9):3281-90
   PubMed Web of Science ®Google Scholar
• Demo SD, Buchholz TJ, Laidig GJ, Biochemical and cellular characterization of the novel proteasome inhibitor PR-171. ASH Annu Meeting Abstr 2005;106(11):1588
   Google Scholar
• O'Connor OA, Stewart AK, Vallone M, A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009;15(22):7085-91
   PubMed Web of Science ®Google Scholar
• Alsina M, Trudel S, Vallone M, Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood 2007;110(11):128a-abstract 411
   Web of Science ®Google Scholar
• Jagannath S, Vij R, Stewart K, Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). ASCO Meeting Abstr 2009;27(15S):8504
   Google Scholar
• diCapua Siegel DS, Martin T, Wang M, Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). ASH Annu Meeting Abstr 2010;116(21):985
   Google Scholar
• Vij R, Kaufman JL, Jakubowiak AJ, Final results from the bortezomib-naive group of PX-171-004, a phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory MM. ASH Annu Meeting Abstr 2011;118(21):813
   Google Scholar
• Vij R, Siegel DS, Kaufman JL, Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM). ASCO Meeting Abstr 2010;28(15 Suppl):8000
   Google Scholar
• Jakubowiak AJ, Siegel DS, Singhal S, Unfavorable cytogenetic characteristics do not adversely impact response rates in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib on the 003 (A1) study. ASH Annu Meeting Abstr 2011;118(21):1875
   Google Scholar
• Badros AZ, Vij R, Martin T, Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency. ASCO Meeting Abstr 2010;28(15 Suppl):8128
   Google Scholar
• Singhal S, Siegel DS, Martin T, Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. ASH Annu Meeting Abstr 2011;118(21):1876
   Google Scholar
• Richardson PG, Weller E, Jagannath S, Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27(34):5713-19
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116(5):679-86
   PubMed Web of Science ®Google Scholar
• Wang M, Bensinger W, Martin T, Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM). ASCO Meeting Abstr 2011;29(15 Suppl):8025
   Google Scholar
• Jakubowiak AJ, Dytfeld D, Jagannath S, Final results of a frontline phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM). ASH Annu Meeting Abstr 2011;118(21):631
   Google Scholar
• Moreau P, Palumbo AP, Stewart AK, A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and dex in patients (Pts) with relapsed multiple myeloma (MM). ASCO Meeting Abstr 2011;29(15 Suppl):TPS225
   Google Scholar
• Sonneveld P, Hacker E, Zweegman S, Carfilzomib combined with thalidomide and dexamethasone (CARTHADEX) as induction treatment prior to high-dose melphalan (HDM) in newly diagnosed patients with multiple myeloma (MM). A trial of the European Myeloma Network EMN. ASH Annu Meeting Abstr 2011;118(21):633
   Google Scholar
• Zhou HJ, Aujay MA, Bennett MK, Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009;52(9):3028-38
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, Mendelson DS, Tolcher AW, A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors. ASCO Meeting Abstr 2011;29(15 Suppl):3075
   Google Scholar
• Kupperman E, Lee EC, Cao Y, Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010;70(5):1970-80
   PubMed Web of Science ®Google Scholar
• Chauhan D, Tian Z, Zhou B, In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011;17(16):5311-21
   PubMed Web of Science ®Google Scholar
• Gupta N, Saleh M, Venkatakrishnan K. Flat-dosing versus BSA-based dosing for MLN9708, an investigational proteasome inhibitor: population pharmacokinetic (PK) analysis of pooled data from 4 phase-1 studies. ASH Annu Meeting Abstr 2011;118(21):1433
   Google Scholar
• Assouline S, Chang J, Rifkin R, MLN9708, a novel, investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma: results of a phase 1 dose-escalation study. ASH Annu Meeting Abstr 2011;118(21):2672
   Google Scholar
• Kumar S, Bensinger WI, Reeder CB, Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: results from a phase 1 dose-escalation study. ASH Annu Meeting Abstr 2011;118(21):816
   Google Scholar
• Richardson PG, Baz R, Wang L, Investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study. ASH Annu Meeting Abstr 2011;118(21):301
   Google Scholar
• Berdeja JG, Richardson PG, Lonial S, Phase 1/2 study of oral MLN9708, a novel, investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). ASH Annu Meeting Abstr 2011;118(21):479
   Google Scholar
• Chauhan D, Hideshima T, Anderson KC. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer 2006;95(8):961-5
   PubMed Web of Science ®Google Scholar
• Chauhan D, Catley L, Li G, A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005;8(5):407-19
   PubMed Web of Science ®Google Scholar
• Chauhan D, Singh A, Brahmandam M, Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008;111(3):1654-64
   PubMed Web of Science ®Google Scholar
• Richardson PG, Spencer A, Cannell P, Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). ASH Annu Meeting Abstr 2011;118(21):302
   Google Scholar
• Dorsey BD, Iqbal M, Chatterjee S, Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 2008;51(4):1068-72
   PubMed Web of Science ®Google Scholar
• Piva R, Ruggeri B, Williams M, CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008;111(5):2765-75
   PubMed Web of Science ®Google Scholar
• Sanchez E, Li M, Steinberg JA, The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol 2010;148(4):569-81
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P, Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98(2):492-4
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341(21):1565-71
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357(21):2133-42
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357(21):2123-32
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A, Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23(11):2147-52
   PubMed Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T, Identification of a primary target of thalidomide teratogenicity. Science 2010;327(5971):1345-50
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118(18):4771-9
   PubMed Web of Science ®Google Scholar
• Li S, Pal R, Monaghan SA, IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood 2011;117(19):5157-65
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Heintel D, Zhang LH, Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011;154(3):325-36
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y, Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96(9):2943-50
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Capone L, Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010;10(2):155-67
   PubMed Web of Science ®Google Scholar
• Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009;69(18):7347-56
   PubMed Web of Science ®Google Scholar
• Gupta D, Treon SP, Shima Y, Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15(12):1950-61
   PubMed Web of Science ®Google Scholar
• Chang DH, Liu N, Klimek V, Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108(2):618-21
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008;14(14):4650-7
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58(7):1033-45
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118(7):2427-37
   PubMed Web of Science ®Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91(9):4082-5
   PubMed Web of Science ®Google Scholar
• Lu L, Payvandi F, Wu L, The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009;77(2):78-86
   PubMed Web of Science ®Google Scholar
• Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev 2010;24(Suppl 1):S13-19
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW, Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163(1):380-6
   PubMed Web of Science ®Google Scholar
• Schey SA, Fields P, Bartlett JB, Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22(16):3269-76
   PubMed Web of Science ®Google Scholar
• Streetly MJ, Gyertson K, Daniel Y, Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008;141(1):41-51
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel D, Baz R, A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. ASH Annu Meeting Abstr 2010;116(21):864
   Google Scholar
• Richardson PG, Siegel DS, Vij R, Randomized, open label phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): phase 2 results. ASH Annu Meeting Abstr 2011;118(21):634
   Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27(30):5008-14
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Hayman SR, Laumann K, Long term outcomes of pomalidomide and dexamethasone in patients with relapsed multiple myeloma: analysis 4 years after the original cohort. ASH Annu Meeting Abstr 2011;118(21):2942
   Google Scholar
• Madan S, Lacy M, Dispenzieri A, Efficacy of Retreatment with immunomodulatory compounds in patients receiving initial therapy for newly diagnosed multiple myeloma. ASH Annu Meeting Abstr 2010;116(21):1964
   Google Scholar
• Madan S, Lacy MQ, Dispenzieri A, Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood 2011;118(7):1763-5
   PubMed Web of Science ®Google Scholar
• Ocio EM, Fernandez-Lazaro D, San-Segundo L, Reversibility of the resistance to lenalidomide and pomalidomide and absence of cross-resistance in a murine model of MM. ASH Annu Meeting Abstr 2011;118(21):134
   Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010;24(11):1934-9
   PubMed Web of Science ®Google Scholar
• Lacy MQ, LaPlant BR, Laumann K, Pomalidomide and dexamethasone in relapsed myeloma: results of 225 patients treated in five cohorts over three years. ASH Annu Meeting Abstr 2011;118(21):3963
   Google Scholar
• Lacy MQ, Allred JB, Gertz MA, Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. Blood 2011;118(11):2970-5
   PubMed Web of Science ®Google Scholar
• Leleu X, Attal M, Arnulf B, High response rates to pomalidomide and dexamethasone in patients with refractory myeloma, final analysis of IFM 2009-02. ASH Annu Meeting Abstr 2011;118(21):812
   Google Scholar
• Leleu X, Attal M, Moreau P, Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009-02. ASH Annu Meeting Abstr 2010;116(21):859
   Google Scholar